Currax Pharmaceuticals is highlighting a peer-reviewed publication supporting the use of combination pharmacotherapy approaches in obesity treatment, based on multiple gut-brain pathways involved in appetite and metabolic regulation.

The review, published in Obesity Science and Practice, examines evidence suggesting that obesity is driven by overlapping biological mechanisms, including energy balance, appetite control and reward-related feeding behaviour.

The authors propose that targeting multiple pathways may offer a more comprehensive approach to long-term weight management than single-mechanism therapies alone, particularly in patients with complex behavioural and metabolic drivers of obesity.

Michael Kyle, chief medical officer at Currax Pharmaceuticals, said: “The heterogeneity of obesity demands a more personalised approach to obesity treatment selection.”

He added that the review highlights the importance of considering biological drivers beyond weight alone, particularly in patients who experience persistent cravings or hedonic eating despite feeling satiated.

The publication reflects a broader trend in obesity research towards mechanistically informed treatment strategies that account for the multifactorial nature of the disease.

The journal, Obesity Science and Practice, is peer reviewed and published in collaboration with The Obesity Society and the World Obesity Federation, with a focus on clinical and translational obesity research.

Currax said the findings align with its focus on chronic disease management and support for therapies designed for long-term weight reduction and maintenance in adults with obesity or overweight with related comorbidities.

The company’s lead therapy, naltrexone HCl/bupropion HCl, is indicated for use alongside diet and lifestyle interventions to support weight reduction and maintenance in appropriate patients.